Net Profit up 42% to Rs 1178 crores for the year
Alembic Pharmaceuticals Limited reported its consolidated financial results for the period ending 31st March 2021.
Financial Highlights for the Quarter
Net Sales for the quarter up 6% to Rs 1280 crores.
Net Profit for the quarter up 12% to Rs 251 crores from Rs 225 crores.
Financial Highlights for the Year
Net sales for FY21 up 17% to Rs 5393 crores against Rs 4606 crores.
Net profit for FY21 up 42% to Rs 1178 crores from Rs 829 crores.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said, “It was an outstanding year with the company recording its highest sales and profit ever. This was led by strong growth in the API and International Business. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted”
International formulations grew 19% to Rs 2942 crores for FY21.
US Generics grew 9% to Rs 2163 crores for FY21
Ex-US International Formulations grew 57% to Rs 779 Crores for FY21.
13 ANDA’s were filed in the quarter and 29 ANDA filings for the year.
R&D spend at 12% of revenue or Rs 670 Crores for the year.
India Branded Formulations Business
India branded formulations business grew 5% to Rs 1497 crores for FY21.
API business grew 38% to Rs 214 crores in the quarter and 35% to Rs 955 crores for FY21.
2 DMF were filed in the quarter, Cumulative DMF fillings.
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)